MorphoMed CSO wins award for best experimental publication in trauma surgery

Dr. Andreas Teuschl, CSO and co-founder of MorphoMed, has won the OeGU (Austrian Society for Trauma Surgery) award 2017 for the best experimental publication in trauma surgery with the paper "A Novel Silk Fiber Based Scaffold for Regeneration of the Anterior Cruciate Ligament: Historical Results from a Sheep Study", published in 2016 in “The American Journal of Sports Medicine” (Am J Sports Med. 2016 Jun;44(6):1547-57.). He will present his work at the annual OeGU meeting from 5 to 7 October 2017 in Salzburg in an invited lecture.

"I am very happy about this award," so Andreas Teuschl, "because it values an excellent scientific work that has been performed over many years and that has led to these extremely impressive data proving that the concept of ligament regeneration is really doable. My thanks go to my excellent colleagues, who have supported me in this work”. This work is a result of the successful translational efforts in the Austrian Cluster for Tissue Regeneration in a cooperation between the Ludwig Boltzmann Institute for Experimental and Clinical Traumatology/AUVA and the University of Applied Sciences Technikum Wien.

About MorphoMed
MorphoMed is a MedTech Start-Up company founded in Vienna in May 2017 focused on the development of new regenerative implants based on its proprietary medical silk technology. Silk can be completely cleaned from its antigenic sericin layer even in complex textile structures such as a braided ACL (anterior cruciate ligament). MorphoMed's lead product RegACL is a regenerative medical silk ACL implant potentially helping thousands of patients after an ACL rupture. Patients can get back to their normal life including sports activities only weeks after surgery. Furthermore; full regeneration of their body’s own natural ligaments is expected over the years and has been successfully demonstrated in a sheep model.

MorphoMed is an associate member of the Austrian Cluster for Tissue Regeneration.

Press contact
Dr. Andreas Teuschl, CSO
MorphoMed GmbH
Email: andreas.teuschl(at)

The sender takes full responsibility for the content of this news item. Content may include forward-looking statements which, at the time they were made, were based on expectations of future events. Readers are cautioned not to rely on these forward-looking statements.

As a life sciences organization based in Vienna, would you like us to promote your news and events? If so, please send your contributions to news(at)